MetaCap

ImmunityBio Inc. Company Profile

NASDAQ: IBRXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

6.02-0.55 (-8.37%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ImmunityBio at a glance

ImmunityBio Inc. (NASDAQ: IBRX) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in San Diego, CA. ImmunityBio is led by Mr. Richard Gerald Adcock and employs about 684 people. The company's shares have traded publicly since 2015.

At a market capitalization of $6.40 billion, it is considered a mid-cap company. Its SEC Central Index Key (CIK) is 0001326110, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does ImmunityBio do?

ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.

Business description based on the company's public filings.

Company information

Legal name
ImmunityBio Inc.
Ticker
NASDAQ: IBRX
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Richard Gerald Adcock
Employees
684
Headquarters
3530 John Hopkins Court, San Diego, CA, United States
Phone
844 696 5235
IPO year
2015
SEC CIK
0001326110
Latest annual report
10-K · Feb 23, 2026

Companies similar to ImmunityBio

IBRX peer companies
CompanyPrice% ChgMarket capCompare
KODKodiak Sciences Inc97.17-0.75%$6.35Bvs IBRX
IMVTImmunovant Inc.31.77-2.31%$6.57Bvs IBRX
SRRKScholar Rock Holding Corporation48.13-4.45%$5.87Bvs IBRX
TWSTTwist Bioscience Corporation103.32-7.44%$7.04Bvs IBRX
CGONCG Oncology Inc.79.47-2.97%$7.10Bvs IBRX
ADPTAdaptive Biotechnologies Corporation27.93-0.43%$4.52Bvs IBRX
PCVXVaxcyte Inc.55.39-5.09%$8.77Bvs IBRX
CRSPCRISPR Therapeutics AG39.10+0.44%$3.79Bvs IBRX

Related